Harrow (HROW) | Financial Analysis & Statements
Harrow Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
89.1M
Gross Profit
70.6M
79.27%
Operating Income
15.6M
17.50%
Net Income
6.6M
7.44%
Balance Sheet Metrics
Total Assets
399.5M
Total Liabilities
347.4M
Shareholders Equity
52.1M
Debt to Equity
6.67
Cash Flow Metrics
Operating Cash Flow
4.7M
Free Cash Flow
8.0M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Harrow Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 272.3M | 199.6M | 130.2M | 88.6M | 72.5M |
| Cost of Goods Sold | 67.9M | 49.2M | 39.6M | 25.4M | 18.2M |
| Gross Profit | 204.4M | 150.4M | 90.6M | 63.2M | 54.3M |
| Gross Margin % | 75.1% | 75.3% | 69.6% | 71.3% | 74.9% |
| Operating Expenses | |||||
| Research & Development | 20.9M | 12.2M | 6.7M | 3.0M | 11.1M |
| Selling, General & Administrative | 152.9M | 129.1M | 83.1M | 58.2M | 41.3M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 173.9M | 141.3M | 89.7M | 61.3M | 52.4M |
| Operating Income | 30.5M | 9.1M | 811.0K | 1.9M | 1.9M |
| Operating Margin % | 11.2% | 4.5% | 0.6% | 2.2% | 2.6% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | 24.2M | 22.8M | 21.3M | 7.2M | - |
| Other Non-Operating Income | -7.7M | -3.6M | -3.2M | -8.7M | -14.3M |
| Pre-tax Income | -1.4M | -17.3M | -23.7M | -14.0M | -17.9M |
| Income Tax | 3.8M | 161.0K | 701.0K | 75.0K | 133.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -5.1M | -17.5M | -24.4M | -14.1M | -18.0M |
| Net Margin % | -1.9% | -8.8% | -18.7% | -15.9% | -24.8% |
| Key Metrics | |||||
| EBITDA | 50.2M | 23.4M | 12.7M | -5.4M | 13.4M |
| EPS (Basic) | $-0.14 | $-0.49 | $-0.75 | $-0.51 | $-0.69 |
| EPS (Diluted) | $-0.14 | $-0.49 | $-0.75 | $-0.51 | $-0.69 |
| Basic Shares Outstanding | 36760461 | 35650714 | 32616777 | 27619608 | 26781159 |
| Diluted Shares Outstanding | 36760461 | 35650714 | 32616777 | 27619608 | 26781159 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Harrow Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 72.9M | 47.2M | 74.1M | 96.3M | 42.2M |
| Short-term Investments | - | 0 | 8.7M | 5.6M | 8.5M |
| Accounts Receivable | 110.9M | 116.4M | 36.3M | 6.2M | 4.5M |
| Inventory | 13.5M | 10.7M | 10.9M | 6.5M | 4.2M |
| Other Current Assets | 2.1M | 3.4M | 1.8M | 118.0K | 92.0K |
| Total Current Assets | 211.8M | 189.7M | 139.5M | 118.3M | 60.7M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 13.7M | 13.9M | 4.6M | 4.3M | 4.1M |
| Goodwill | 177.0M | 187.4M | 162.7M | 26.5M | 17.8M |
| Intangible Assets | 176.4M | 186.7M | 162.0M | 25.8M | 17.1M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | - | 0 | 2.0M | 0 |
| Total Non-Current Assets | 187.7M | 199.3M | 172.7M | 39.1M | 37.7M |
| Total Assets | 399.5M | 389.0M | 312.2M | 157.4M | 98.3M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 35.4M | 38.8M | 21.4M | 6.4M | 5.2M |
| Short-term Debt | 887.0K | 497.0K | 806.0K | 723.0K | 280.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 96.3M | 91.3M | 49.3M | 18.6M | 9.7M |
| Non-Current Liabilities | |||||
| Long-term Debt | 251.1M | 228.3M | 189.7M | 111.5M | 77.7M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 251.1M | 228.3M | 192.4M | 111.5M | 77.7M |
| Total Liabilities | 347.4M | 319.7M | 241.8M | 130.1M | 87.4M |
| Equity | |||||
| Common Stock | 37.0K | 35.0K | 35.0K | 30.0K | 27.0K |
| Retained Earnings | -156.5M | -151.4M | -133.9M | -109.5M | -95.4M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 52.1M | 69.3M | 70.4M | 27.2M | 10.9M |
| Key Metrics | |||||
| Total Debt | 252.0M | 228.8M | 190.5M | 112.2M | 78.0M |
| Working Capital | 115.4M | 98.3M | 90.1M | 99.6M | 50.9M |
Balance Sheet Composition
Harrow Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -5.1M | -17.5M | -24.4M | -14.1M | -18.0M |
| Depreciation & Amortization | 19.7M | 14.5M | 12.3M | 3.7M | 2.4M |
| Stock-Based Compensation | 12.5M | 17.6M | 15.7M | 8.0M | 5.7M |
| Working Capital Changes | -1.7M | -42.6M | -2.9M | -3.2M | -406.0K |
| Operating Cash Flow | 29.4M | -23.7M | 4.8M | -4.8M | -9.6M |
| Investing Activities | |||||
| Capital Expenditures | -887.0K | -1.6M | -1.5M | -2.6M | -1.8M |
| Acquisitions | -4.4M | - | - | - | 9.8M |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | 0 | 5.5M | - | 0 | 9.8M |
| Investing Cash Flow | -5.2M | 3.9M | -1.5M | 3.4M | 17.9M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | 0 | -11.0M |
| Dividends Paid | - | - | - | 0 | -127.0K |
| Debt Issuance | 244.4M | 29.8M | 134.4M | 31.7M | 71.1M |
| Debt Repayment | -230.9M | 0 | -59.8M | -18.0K | -7.0K |
| Financing Cash Flow | -13.2M | 27.4M | 126.1M | 53.5M | 51.4M |
| Free Cash Flow | 42.8M | -60.9M | -148.7M | -6.1M | -23.4M |
| Net Change in Cash | 11.0M | 7.6M | 129.5M | 52.1M | 59.7M |
Cash Flow Trend
Harrow Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-277.07
Forward P/E
14.39
Price to Book
27.78
Price to Sales
5.35
PEG Ratio
52.64
Profitability Ratios
Profit Margin
-1.89%
Operating Margin
17.50%
Return on Equity
-8.47%
Return on Assets
4.84%
Financial Health
Current Ratio
2.20
Debt to Equity
483.72
Beta
0.31
Per Share Data
EPS (TTM)
$-0.14
Book Value per Share
$1.41
Revenue per Share
$7.41
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| HROW | 1.4B | -277.07 | 27.78 | -8.47% | -1.89% | 483.72 |
| Zoetis | 49.8B | 19.58 | 15.04 | 65.99% | 28.24% | 279.59 |
| Haleon Plc - ADR | 42.4B | 18.72 | 1.88 | 10.27% | 15.11% | 52.37 |
| Dynavax Technologies | 1.8B | 54.60 | 3.41 | -7.14% | -13.13% | 54.15 |
| Ani Pharmaceuticals | 1.8B | 24.08 | 3.10 | 16.16% | 8.87% | 116.19 |
| Perrigo Company plc | 1.6B | 2,818.00 | 0.55 | -38.66% | -33.51% | 131.16 |
Financial data is updated regularly. All figures are in the company's reporting currency.






